Malaria Vaccine

World's second malaria vaccine gets WHO approval: Serum Institute of India World's second malaria vaccine gets WHO approval: Serum Institute of India

The World Health Organization (WHO) has made several significant recommendations related to vaccines and immunization in a recent update: The World Health Organization (WHO) has made several significant recommendations related to vaccines and immunization in a recent update:

Malaria Prevention:

WHO recommends a new malaria vaccine called R21/Matrix-M for the prevention of malaria in children. WHO recommends a new malaria vaccine called R21/Matrix-M for the prevention of malaria in children.

Malaria Prevention:

This vaccine, along with the previously recommended RTS,S/AS01 vaccine, is expected to have a high impact on preventing malaria in children, especially in the African Region. This vaccine, along with the previously recommended RTS,S/AS01 vaccine, is expected to have a high impact on preventing malaria in children, especially in the African Region.

Malaria Prevention:

Demand for malaria vaccines is high, and the addition of R21 is expected to address the supply shortage. Demand for malaria vaccines is high, and the addition of R21 is expected to address the supply shortage.

R21 Malaria Vaccine Key Features:

– The R21 vaccine has demonstrated high efficacy when given before the high transmission season, reducing symptomatic malaria cases by 75% during the 12 months following a 3-dose series. – The R21 vaccine has demonstrated high efficacy when given before the high transmission season, reducing symptomatic malaria cases by 75% during the 12 months following a 3-dose series.

R21 Malaria Vaccine Key Features:

– Good efficacy (66%) is observed when given in an age-based schedule. – It is cost-effective, with a price range of US$2 to US$4 per dose. – Safety has been demonstrated in clinical trials. – Good efficacy (66%) is observed when given in an age-based schedule. – It is cost-effective, with a price range of US$2 to US$4 per dose. – Safety has been demonstrated in clinical trials.

R21 Malaria Vaccine Key Features:

The choice between R21 and RTS,S vaccines should be based on programmatic considerations, vaccine supply, and affordability. The choice between R21 and RTS,S vaccines should be based on programmatic considerations, vaccine supply, and affordability.

Dengue Vaccine:

WHO recommends the introduction of a live-attenuated quadrivalent dengue vaccine (TAK-003) in settings with high dengue disease burden and transmission. WHO recommends the introduction of a live-attenuated quadrivalent dengue vaccine (TAK-003) in settings with high dengue disease burden and transmission.

Dengue Vaccine:

The vaccine is recommended for children aged 6 to 16 years, introduced 1-2 years prior to the peak incidence of dengue-related hospitalizations. The vaccine is recommended for children aged 6 to 16 years, introduced 1-2 years prior to the peak incidence of dengue-related hospitalizations.

Dengue Vaccine:

Community engagement and communication strategies are crucial for vaccine introduction. Community engagement and communication strategies are crucial for vaccine introduction.

Meningitis Vaccine:

WHO recommends the introduction of the novel pentavalent meningococcal conjugate vaccine (Men5CV) in the African meningitis belt. WHO recommends the introduction of the novel pentavalent meningococcal conjugate vaccine (Men5CV) in the African meningitis belt.

Meningitis Vaccine:

– It should be administered in a single-dose schedule at 9 to 18 months of age. – Catch-up campaigns are recommended in high-risk countries and districts targeting individuals aged 1 to 19 years. – It should be administered in a single-dose schedule at 9 to 18 months of age. – Catch-up campaigns are recommended in high-risk countries and districts targeting individuals aged 1 to 19 years.

COVID-19 Vaccine:

SAGE (Strategic Advisory Group of Experts on Immunization) recommends a simplified single-dose regimen for most COVID-19 vaccines to improve acceptance and uptake. SAGE (Strategic Advisory Group of Experts on Immunization) recommends a simplified single-dose regimen for most COVID-19 vaccines to improve acceptance and uptake.

COVID-19 Vaccine:

Monovalent Omicron XBB vaccines are found to provide enhanced protection compared to other variants. Monovalent Omicron XBB vaccines are found to provide enhanced protection compared to other variants.

COVID-19 Vaccine:

Any available WHO emergency-use listed or prequalified vaccine can be used in the absence of monovalent XBB vaccines. Any available WHO emergency-use listed or prequalified vaccine can be used in the absence of monovalent XBB vaccines.

IA2030 (Immunization Agenda 2030):

Progress against IA2030 indicators was impacted by the COVID-19 pandemic, particularly in low-income countries and vulnerable populations. Progress against IA2030 indicators was impacted by the COVID-19 pandemic, particularly in low-income countries and vulnerable populations.

IA2030 (Immunization Agenda 2030):

A shared action agenda for 2023-2024 aims to align efforts to regain control of immunization programs, promote equity, control measles, secure investment, introduce recommended vaccines, and advance vaccination in adolescence. A shared action agenda for 2023-2024 aims to align efforts to regain control of immunization programs, promote equity, control measles, secure investment, introduce recommended vaccines, and advance vaccination in adolescence.

These recommendations reflect the WHO's commitment to improving public health through immunization and addressing significant health challenges such as malaria, dengue, meningitis, and COVID-19. These recommendations reflect the WHO's commitment to improving public health through immunization and addressing significant health challenges such as malaria, dengue, meningitis, and COVID-19.